CompletedPhase 2NCT06114537
The AXIS Study: the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in Retinoschisis
Studying X-linked retinoschisis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Principal Investigator
- Camiel JF Boon, Prof. dr.Amsterdam UMC
- Intervention
- Acetazolamide(drug)
- Enrollment
- 19 target
- Eligibility
- 12 years · MALE
- Timeline
- 2023 – 2024
Study locations (1)
- Amsterdam University Medical Centers, Amsterdam, North Holland, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06114537 on ClinicalTrials.govOther trials for X-linked retinoschisis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06289452Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked RetinoschisisInnoVec Biotherapeutics Inc.
- RECRUITINGEARLY PHASE1NCT06345898Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)West China Hospital
- RECRUITINGPHASE1, PHASE2NCT05878860ATSN-201 Gene Therapy in RS1-Associated X-linked RetinoschisisAtsena Therapeutics Inc.
- RECRUITINGNANCT05814952Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine